DiscGenics Announces Positive Two-Year Clinical Data from U.S. Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
- Written by PR Newswire
 |
Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with lumbar DDD.
SALT LAKE CITY, Jan. 25, 2023 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company...
